Phase IIIB Switching From Intravenous to Subcutaneous Study
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether switching to subcutaneous administration of
abatacept will be safe in participants with rheumatoid arthritis who previously received
long-term therapy with intravenous abatacept